| P50 | author | Itziar Miguéliz | Q39400013 |
| | José Luis Vizmanos | Q39400047 |
| | Francisco Javier Novo Villaverde | Q39400083 |
| P2093 | author name string | Cristina Ormazábal | |
| | Ion Cristobal | |
| | Cristina Hurtado | |
| | Ignacio Erquiaga | |
| | Paula Aranaz | |
| | Marina García-Delgado | |
| P2860 | cites work | cbl-3: a new mammalian cbl family protein | Q22009959 |
| | Recurring mutations found by sequencing an acute myeloid leukemia genome | Q24634204 |
| | Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 | Q27687464 |
| | Primer3 on the WWW for general users and for biologist programmers | Q27861030 |
| | Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders | Q29614510 |
| | Mutation in TET2 in myeloid cancers | Q29619292 |
| | CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases | Q33528991 |
| | Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias | Q33647411 |
| | Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia | Q33722741 |
| | Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. | Q33925815 |
| | Kinase mutations in human disease: interpreting genotype-phenotype relationships | Q34088851 |
| | Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia | Q34130332 |
| | Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism | Q34186690 |
| | c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment | Q34250032 |
| | Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. | Q34578265 |
| | CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome | Q43112720 |
| | The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration | Q43161822 |
| | Mutations of ASXL1 gene in myeloproliferative neoplasms. | Q43456344 |
| | MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Q44008600 |
| | Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin | Q44756897 |
| | Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders | Q46513376 |
| | Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia | Q47258886 |
| | Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms | Q47960630 |
| | RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. | Q51771337 |
| | Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. | Q54426186 |
| | Myeloid Leukemia Development in c-Cbl RING Finger Mutant Mice Is Dependent on FLT3 Signaling | Q54642331 |
| | Flt3-dependent transformation by inactivating c-Cbl mutations in AML | Q57269958 |
| | Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1 | Q57740696 |
| | Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias | Q81774094 |
| | Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations | Q84512741 |
| | Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML | Q84626274 |
| | Oncogenic tyrosine kinases and the DNA-damage response | Q34665985 |
| | MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. | Q34775393 |
| | Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases | Q35169572 |
| | JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis | Q35635353 |
| | Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia | Q35901705 |
| | Negative regulation of PTK signalling by Cbl proteins | Q36194521 |
| | c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses | Q36280423 |
| | Regulating the regulator: negative regulation of Cbl ubiquitin ligases | Q36365848 |
| | The Cbl family proteins: ring leaders in regulation of cell signaling | Q36495318 |
| | Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy. | Q36857947 |
| | Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms | Q36946576 |
| | Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera | Q37112871 |
| | Familial chronic myeloproliferative disorders: the state of the art. | Q37165474 |
| | JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science | Q37255016 |
| | Genetic complexity of myeloproliferative neoplasms. | Q37255024 |
| | Mutations in CBL occur frequently in juvenile myelomonocytic leukemia | Q37334614 |
| | Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies | Q37701292 |
| | Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms | Q37710951 |
| | Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms. | Q37765082 |
| | CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. | Q39874787 |
| | High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations | Q40108060 |
| | E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. | Q42459486 |
| | Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms | Q42795736 |
| | 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies | Q43078973 |
| | A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes. | Q43086317 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1234-1241 | |
| P577 | publication date | 2012-02-07 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2. | |
| P478 | volume | 97 | |